Boehringer Ingelheim and Eli Lilly's Jardiance gets big
lift from heart failure indications
Boehringer Ingelheim reported its full-year 2022 sales figures, showing more evidence of the momentum approvals to treat heart failure have brought for Jardiance. The diabetes drug generated 5.8 billion euros ($6.1 billion) of sales in 2022, a 39% increase on 2021.
No comments:
Post a Comment